Is the epithelial-to-mesenchymal transition clinically relevant for the cancer patient?

Current Pharmaceutical Biotechnology

Volumn 12, Issue 11, 2011, Pages 1891-1899

  Krasnapolski, Martin A ^a   Todaro, Laura B ^a   de Kier Joffé, Elisa Bal ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Biomarkers; Cancer; Emt; Molecular mechanism

Indexed keywords

BETA CATENIN; CLAUDIN; CYCLOPAMINE; DASATINIB; ENTINOSTAT; FRESOLIMUMAB; GEFITINIB; GELATINASE A; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; OCCLUDIN; SCLEROPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CARCINOMA; CELL SURFACE; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE SILENCING; GLIOMA; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WOUND HEALING;

EID: 83455210823     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798377021     Document Type: Article

References (85)

1. Voulgari, A.; Pintzas, A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta, 2009, 1796(2), 75-90.
2. Wu, Y.; Zhou, B. P. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim. Biophys. Sin., (Shanghai) 2008, 40(7), 643-650.
3. Tse, J. C.; Kalluri, R. Mechanisms of metastasis: epithelial-tomesenchymal transition and contribution of tumor microenvironment. J. Cell Biochem., 2007, 101(4), 816-829.
4. Garber, K. Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. J. Natl. Cancer Inst., 2008, 100(4), 232-233, 239.
5. Tarin, D.; Thompson, E. W.; Newgreen, D. F. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res., 2005, 65(14), 5996-6000; discussion 6000-5991.
6. Kalluri, R.; Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest, 2009, 119(6), 1420-1428.
7. Perez-Pomares, J. M.; Munoz-Chapuli, R. Epithelial-mesenchymal transitions: a mesodermal cell strategy for evolutive innovation in Metazoans. Anat. Rec., 2002, 268(3), 343-351.
8. Flanders, K.C. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol., 2004, 85(2), 47-64.
9. Thompson, E. W.; Torri, J.; Sabol, M.; Sommers, C. L.; Byers, S.; Valverius, E. M.; Martin, G. R.; Lippman, M. E.; Stampfer, M. R.; Dickson, R. B. Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin. Exp. Metastasis, 1994, 12(3), 181-194.
10. Turley, E. A.; Veiseh, M.; Radisky, D. C.; Bissell, M. J. Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression? Nat. Clin. Pract. Oncol., 2008, 5(5), 280-290.
11. Xue, C.; Plieth, D.; Venkov, C.; Xu, C.; Neilson, E.G. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res., 2003, 63(12), 3386-3394.
12. Acloque, H.; Adams, M. S.; Fishwick, K.; Bronner-Fraser, M.; Nieto, M. A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest., 2009, 119(6), 1438-1449.
13. Kalluri, R.; Neilson, E. G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest., 2003, 112(12), 1776-1784.
14. Ramos, C.; Becerril, C.; Montano, M.; Garcia-De-Alba, C.; Ramirez, R.; Checa, M.; Pardo, A.; Selman, M. FGF-1 reverts epithelialmesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am. J. Physiol. Lung Cell Mol. Physiol., 2010, 299(2),L222-231
15. Wells, A.; Yates, C.; Shepard, C. R. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin. Exp. Metastasis, 2008, 25(6), 621-628.
16. Yang, Z.; Zhang, X.; Gang, H.; Li, X.; Li, Z.; Wang, T.; Han, J.; Luo, T.; Wen, F.; Wu, X. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem. Biophys. Res. Commun., 2007, 358(3), 925-930.
17. Zeisberg, M.; Strutz, F.; Muller, G.A. Renal fibrosis: an update. Curr. Opin. Nephrol. Hypertens, 2001, 10(3), 315-320.
18. Carpenter, P. M.; Wang-Rodriguez, J.; Chan, O. T.; Wilczynski, S. P. Laminin 5 expression in metaplastic breast carcinomas. Am. J. Surg. Pathol., 2008, 32(3), 345-353.
19. Giannelli, G.; Milillo, L.; Marinosci, F.; Lo Muzio, L.; Serpico, R.; Antonaci, S. Altered expression of integrins and basement membrane proteins in malignant and pre-malignant lesions of oral mucosa. J. Biol. Regul. Homeost Agents, 2001, 15(4), 375-380.
20. Giannelli, G.; Fransvea, E.; Bergamini, C.; Marinosci, F.; Antonaci, S. Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin. Cancer Res., 2003, 9(10 Pt 1), 3684-3691.
21. Ljubimova, J. Y.; Lakhter, A. J.; Loksh, A.; Yong, W. H.; Riedinger, M. S.; Miner, J. H.; Sorokin, L. M.; Ljubimov, A. V.; Black, K. L. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res., 2001, 61(14), 5601-5610.
22. Takkunen, M.; Ainola, M.; Vainionpaa, N.; Grenman, R.; Patarroyo, M.; Garcia de Herreros, A.; Konttinen, Y. T.; Virtanen, I. Epithelial-mesenchymal transition downregulates laminin alpha5 chain and upregulates laminin alpha4 chain in oral squamous carcinoma cells. Histochem. Cell Biol., 2008, 130(3), 509-525.
23. Lu, Z.; Ghosh, S.; Wang, Z.; Hunter, T. Downregulation of caveolin- 1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell, 2003, 4(6), 499-515.
24. Lin, C.Y.; Lin, C. J.; Chen, K. H.; Wu, J. C.; Huang, S. H.; Wang, S. M. Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett., 2006, 580(13), 3042-3050.
25. Huber, M. A.; Kraut, N.; Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol., 2005, 17(5), 548-558.
26. Kuphal, S.; Bosserhoff, A.K. Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene, 2006, 25(2), 248-259.
27. Knirsh, R.; Ben-Dror, I.; Spangler, B.; Matthews, G.D.; Kuphal, S.; Bosserhoff, A.K.; Vardimon, L. Loss of E-cadherin-mediated cellcell contacts activates a novel mechanism for up-regulation of the proto-oncogene c-Jun. Mol. Biol. Cell, 2009, 20(7), 2121-2129.
28. Walsh, F. S.; Barton, C. H.; Putt, W.; Moore, S. E.; Kelsell, D.; Spurr, N.; Goodfellow, P. N. N-cadherin gene maps to human chromosome 18 and is not linked to the E-cadherin gene. J. Neurochem., 1990, 55(3), 805-812.
29. Shintani, Y.; Fukumoto, Y.; Chaika, N.; Svoboda, R.; Wheelock, M.J.; Johnson, K.R. Collagen I-mediated up-regulation of Ncadherin requires cooperative signals from integrins and discoidin domain receptor 1. J. Cell Biol., 2008, 180(6), 1277-1289.
30. Ikenouchi, J.; Matsuda, M.; Furuse, M.; Tsukita, S. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J. Cell Sci., 2003, 116(Pt 10), 1959-1967.
31. Maschler, S.; Wirl, G.; Spring, H.; Bredow, D. V.; Sordat, I.; Beug, H.; Reichmann, E. Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene, 2005, 24(12), 2032-2041.
32. Xu, Z.; Shen, M. X.; Ma, D. Z.; Wang, L. Y.; Zha, X. L. TGFbeta1- promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-beta1-enhanced cell migration in SMMC-7721 cells. Cell Res., 2003, 13(5), 343-350.
33. Bates, R. C.; Mercurio, A. M. The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol. Ther., 2005, 4(4), 365-370.
34. Ramos, D. M.; Dang, D.; Sadler, S. The role of the integrin alpha v beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res., 2009, 29(1), 125-130.
35. Maeyama, M.; Koga, H.; Selvendiran, K.; Yanagimoto, C.; Hanada, S.; Taniguchi, E.; Kawaguchi, T.; Harada, M.; Ueno, T.; Sata, M. Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. Cancer, 2008, 113(10), 2823-2831.
36. Iwatsuki, M.; Mimori, K.; Yokobori, T.; Ishi, H.; Beppu, T.; Nakamori, S.; Baba, H.; Mori, M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci., 2010, 101(2), 293-299.
37. Zeisberg, M.; Neilson, E.G. Biomarkers for epithelialmesenchymal transitions. J. Clin. Invest., 2009, 119(6), 1429-1437.
38. Arima, Y.; Inoue, Y.; Shibata, T.; Hayashi, H.; Nagano, O.; Saya, H.; Taya, Y. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res., 2008, 68(13), 5104-5112.
39. Ramaswamy, S.; Ross, K. N.; Lander, E. S.; Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nat. Genet., 2003, 33(1), 49-54.
40. Mani, S. A.; Yang, J.; Brooks, M.; schwaninger, R.; Zhou, A.; Miura, N.; Kutok, J.; Hartwell, K.; Richardson, A. L.; Weinberg, R. A. Mesenchyme forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers Proc. Natl. Acad. Sci. USA, 2007, 104, 10069-10074.
41. Scherr, M.; Venturini, L.; Eder, M. Lentiviral Vector-Mediated Expression of pre-miRNAs and AntagomiRs. Methods Mol. Biol., 2010, 614, 175-185.
42. Zavadil, J.; Narasimhan, M.; Blumenberg, M.; Schneider, R. J. Transforming growth factor-beta and microRNA:mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs., 2007, 185(1-3), 157-161.
43. Gregory, P. A.; Bert, A. G.; Paterson, E. L.; Barry, S. C.; Tsykin, A.; Farshid, G.; Vadas, M. A.; Khew-Goodall, Y.; Goodall, G. J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol., 2008, 10(5), 593-601.
44. Vrba, L.; Jensen, T. J.; Garbe, J. C.; Heimark, R. L.; Cress, A. E.; Dickinson, S.; Stampfer, M. R.; Futscher, B. W. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE, 2010, 5(1), e8697.
45. Khew-Goodall, Y.; Goodall, G. J. Myc-modulated miR-9 makes more metastases. Nat. Cell Biol., 2010, 12(3), 209-211.
46. Li, Y.; Guessous, F.; Zhang, Y.; Dipierro, C.; Kefas, B.; Johnson, E.; Marcinkiewicz, L.; Jiang, J.; Yang, Y.; Schmittgen, T.D.; Lopes, B.; Schiff, D.; Purow, B.; Abounader, R. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res., 2009, 69(19), 7569-7576.
47. Janda, E.; Lehmann, K.; Killisch, I.; Jechlinger, M.; Herzig, M.; Downward, J.; Beug, H.; Grunert, S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol., 2002, 156(2), 299-313.
48. Huber, M. A.; Azoitei, N.; Baumann, B.; Grunert, S.; Sommer, A.; Pehamberger, H.; Kraut, N.; Beug, H.; Wirth, T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest., 2004, 114(4), 569-581.
49. Acevedo, V. D.; Gangula, R. D.; Freeman, K. W.; Li, R.; Zhang, Y.; Wang, F.; Ayala, G. E.; Peterson, L. E.; Ittmann, M.; Spencer, D.M. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell, 2007, 12(6), 559-571.
50. Graham, T. R.; Zhau, H. E.; Odero-Marah, V. A.; Osunkoya, A. O.; Kimbro, K. S.; Tighiouart, M.; Liu, T.; Simons, J. W.; O'Regan, R. M. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res., 2008, 68(7), 2479-2488.
51. Sivakumar, R.; Koga, H.; Selvendiran, K.; Maeyama, M.; Ueno, T.; Sata, M. Autocrine loop for IGF-I receptor signaling in SLUGmediated epithelial-mesenchymal transition. Int. J. Oncol., 2009, 34(2), 329-338.
52. Kim, H. J.; Litzenburger, B. C.; Cui, X.; Delgado, D. A.; Grabiner, B. C.; Lin, X.; Lewis, M. T.; Gottardis, M. M.; Wong, T. W.; Attar, R. M.; Carboni, J. M.; Lee, A.V. Constitutively active type I insulin- like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NFkappaB and snail. Mol. Cell Biol., 2007, 27(8), 3165-3175.
53. Lo, H. W.; Hsu, S. C.; Xia, W.; Cao, X.; Shih, J. Y.; Wei, Y.; Abbruzzese, J. L.; Hortobagyi, G. N.; Hung, M. C. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res., 2007, 67(19), 9066-9076.
54. Mandal, M.; Myers, J. N.; Lippman, S. M.; Johnson, F. M.; Williams, M. D.; Rayala, S.; Ohshiro, K.; Rosenthal, D. I.; Weber, R. S.; Gallick, G. E.; El-Naggar, A. K. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer, 2008, 112(9), 2088-2100.
55. Kim, K.; Lu, Z.; Hay, E. D. Direct evidence for a role of betacatenin/ LEF-1 signaling pathway in induction of EMT. Cell Biol. Int., 2002, 26(5), 463-476.
56. Sanchez, J. F.; Sniderhan, L. F.; Williamson, A. L.; Fan, S.; Chakraborty-Sett, S.; Maggirwar, S. B. Glycogen synthase kinase 3betamediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol. Cell Biol., 2003, 23(13), 4649-4662.
57. Zhou, B. P.; Deng, J.; Xia, W.; Xu, J.; Li, Y. M.; Gunduz, M.; Hung, M. C. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol., 2004, 6(10), 931-940.
58. Peinado, H.; Olmeda, D.; Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer, 2007, 7(6), 415-428.
59. Jung, J. W.; Hwang, S. Y.; Hwang, J. S.; Oh, E. S.; Park, S.; Han, I.O. Ionising radiation induces changes associated with epithelialmesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur. J. Cancer, 2007, 43(7), 1214-1224.
60. Yang, M. H.; Wu, M. Z.; Chiou, S. H.; Chen, P. M.; Chang, S. Y.; Liu, C. J.; Teng, S. C.; Wu, K. J. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol., 2008, 10(3), 295-305.
61. Yoshida, S.; Furukawa, N.; Haruta, S.; Tanase, Y.; Kanayama, S.; Noguchi, T.; Sakata, M.; Yamada, Y.; Oi, H.; Kobayashi, H. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int. J. Gynecol. Cancer, 2009, 19(6), 992-997.
62. Yang, M. H.; Wu, K. J. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle, 2008, 7(14), 2090-2096.
63. Logullo, A. F.; Nonogaki, S.; Pasini, F. S.; Osorio, C. A.; Soares, F. A.; Brentani, M. M. Concomitant expression of epithelialmesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol. Rep., 2010, 23(2), 313-320.
64. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A. S.; Ali, S.; Abbruzzese, J. L.; Gallick, G. E.; Sarkar, F. H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res., 2009, 69(6), 2400-2407.
65. Rho, J. K.; Choi, Y. J.; Lee, J. K.; Ryoo, B. Y.; Na, II.; Yang, S. H.; Kim, C. H.; Lee, J.C. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer, 2009, 63(2), 219-226.
66. Giannelli, G.; Azzariti, A.; Fransvea, E.; Porcelli, L.; Antonaci, S.; Paradiso, A. Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. Br. J. Cancer, 2004, 91(11), 1964-1969.
67. Konecny, G. E.; Venkatesan, N.; Yang, G.; Dering, J.; Ginther, C.; Finn, R.; Rahmeh, M.; Fejzo, M. S.; Toft, D.; Jiang, S.W.; Slamon, D. J.; Podratz, K. C. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br. J. Cancer, 2008, 98(6), 1076-1084.
68. Yauch, R. L.; Januario, T.; Eberhard, D. A.; Cavet, G.; Zhu, W.; Fu, L.; Pham, T. Q.; Soriano, R.; Stinson, J.; Seshagiri, S.; Modrusan, Z.; Lin, C. Y.; O'Neill, V.; Amler, L. C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res., 2005, 11(24 Pt 1), 8686-8698.
69. Giannelli, G.; Azzariti, A.; Sgarra, C.; Porcelli, L.; Antonaci, S.; Paradiso, A. ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem. Pharmacol., 2006, 71(4), 479-485.
70. Shrader, M.; Pino, M.S.; Brown, G.; Black, P.; Adam, L.; Bar-Eli, M.; Dinney, C. P.; McConkey, D. J. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol. Cancer Ther., 2007, 6(1), 277-285.
71. Frederick, B. A.; Helfrich, B. A.; Coldren, C. D.; Zheng, D.; Chan, D.; Bunn, P. A. Jr.; Raben, D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol. Cancer Ther., 2007, 6(6), 1683-1691.
72. Yang, A. D.; Fan, F.; Camp, E. R.; van Buren, G.; Liu, W.; Somcio, R.; Gray, M. J.; Cheng, H.; Hoff, P.M.; Ellis, L.M. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res., 2006, 12(14 Pt 1), 4147-4153.
73. Shah, A. N.; Summy, J. M.; Zhang, J.; Park, S. I.; Parikh, N. U.; Gallick, G. E. Development and characterization of gemcitabineresistant pancreatic tumor cells. Ann. Surg. Oncol., 2007, 14(12), 3629-3637.
74. Kajiyama, H.; Shibata, K.; Terauchi, M.; Yamashita, M.; Ino, K.; Nawa, A.; Kikkawa, F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol., 2007, 31(2), 277-283.
75. Witta, S. E.; Gemmill, R. M.; Hirsch, F. R.; Coldren, C. D.; Hedman, K.; Ravdel, L.; Helfrich, B.; Dziadziuszko, R.; Chan, D.C.; Sugita, M.; Chan, Z.; Baron, A.; Franklin, W.; Drabkin, H. A.; Girard, L.; Gazdar, A. F.; Minna, J. D.; Bunn, P. A. Jr. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res., 2006, 66(2), 944-950.
76. Kent, O. A.; Mullendore, M.; Wentzel, E. A.; Lopez-Romero, P.; Tan, A. C.; Alvarez, H.; West, K.; Ochs, M. F.; Hidalgo, M.; Arking, D. E.; Maitra, A.; Mendell, J. T. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol. Ther., 2009, 8(21), 2013-2024.
77. Li, Y.; VandenBoom, T. G 2nd.; Kong, D.; Wang, Z.; Ali, S.; Philip, P. A.; Sarkar, F. H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res., 2009, 69(16), 6704-6712.
78. Finn, R. S.; Dering, J.; Ginther, C.; Wilson, C. A.; Glaspy, P.; Tchekmedyian, N.; Slamon, D. J. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative breast cancer cell lines growing in vitro. Breast Cancer Res. Treat., 2007, 105(3), 319-326.
79. Feldmann, G.; Dhara, S.; Fendrich, V.; Bedja, D.; Beaty, R.; Mullendore, M.; Karikari, C.; Alvarez, H.; Iacobuzio-Donahue, C.; Jimeno, A.; Gabrielson, K.L.; Matsui, W.; Maitra, A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res., 2007, 67(5), 2187-2196.
80. Olmeda, D.; Jorda, M.; Peinado, H.; Fabra, A.; Cano, A. Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene, 2007, 26(13), 1862-1874.
81. Fuchs, B.C.; Fujii, T.; Dorfman, J. D.; Goodwin, J. M.; Zhu, A. X.; Lanuti, M.; Tanabe, K. K. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res., 2008, 68(7), 2391-2399.
82. Moore, L.D.; Isayeva, T.; Siegal, G.P.; Ponnazhagan, S. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clin. Cancer Res., 2008, 14(15), 4961-4970.
83. Tan, A. R.; Alexe, G.; Reiss, M. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res. Treat., 2009, 115(3), 453-495.
84. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005, 438(7068), 685-689.
85. Scherr, M.; Venturini, L.; Battmer, K.; Schaller-Schoenitz, M.; Schaefer, D.; Dallmann, I.; Ganser, A.; Eder, M. Lentivirusmediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res., 2007, 35(22), e149.